 | |
| Company type | Public |
|---|---|
|
Nasdaq:
AGIO Russell 1000 Component | |
| Industry | Pharmaceuticals |
| Founded | 2008 |
| Headquarters | , United States |
Key people | Brian Goff ( CEO) |
| Revenue |  $118 Million(2019)
[1] |
Number of employees | 536 |
| Website |
agios |
| Footnotes / references Foundation [2] | |
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. [3] The company was founded in 2008 (or 2007) [4] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. [2] [5] The company tendered an initial public offering in July 2013. [6]: Table 1
History
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios. [4]
In May 2016, the company announced it would launch partnership with Celgene, [7] developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments. [8]
In April 2017, the company raised $250 million in a new stock offering in anticipation of approval for its first cancer drug, enasidenib, by the US Food and Drug Administration. [9]
In December 2017, the company filed a New Drug Application with the US FDA for ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. [10]
In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds. [11]
In April 2022, the FDA approved mitapivat as first disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase deficiency. [12]
Corporate governance
As of August 2022 [update], Agios' CEO is Brian Goff. [13]
Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ. [4] [6]
References
- ^ "Agios Reports Fourth Quarter and Full Year 2019 Financial Results – Agios Pharmaceuticals, Inc".
- ^ a b Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. (ed.). The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.
- ^ "About Us".
- ^
a
b
c Pollack, Andrew (February 5, 2012).
"Sloan-Kettering Chief Is Accused of Taking Research".
The New York Times.
- ^ "AGIOS PHARMACEUTICALS, INC". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.
- ^
a
b Huggett, Brady (December 2013).
"Burning Bright".
Nat. Biotechnol. Vol. 31, no. 12. pp. 1068–71.
- ^ "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN. 17 May 2016.
- ^ Williams, Sean (3 June 2016). "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016". The Moteley Fool. Retrieved 13 July 2018.
- ^ "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.
- ^ Agios Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2017.
- ^ "Agios Announces Pricing of $256 Million Public Offering of Common Stock". www.nasdaq.com. Retrieved 2020-03-12.
- ^ "Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency". Agios. Cambridge, MA. 17 February 2022. Retrieved 24 April 2023.
- ^ "Agios Appoints Brian Goff as Chief Executive Officer".
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
- Pharmaceutical companies of the United States
- Pharmaceutical companies established in 2008
- Companies based in Cambridge, Massachusetts
- Companies listed on the Nasdaq
- Health care companies based in Massachusetts
- 2013 initial public offerings
- 2008 establishments in Massachusetts
- American companies established in 2008
- Medical company stubs
|
| |
| Company type | Public |
|---|---|
|
Nasdaq:
AGIO Russell 1000 Component | |
| Industry | Pharmaceuticals |
| Founded | 2008 |
| Headquarters | , United States |
Key people | Brian Goff ( CEO) |
| Revenue | $118 Million(2019)
[1] |
Number of employees | 536 |
| Website |
agios |
| Footnotes / references Foundation [2] | |
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. [3] The company was founded in 2008 (or 2007) [4] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. [2] [5] The company tendered an initial public offering in July 2013. [6]: Table 1
History
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios. [4]
In May 2016, the company announced it would launch partnership with Celgene, [7] developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments. [8]
In April 2017, the company raised $250 million in a new stock offering in anticipation of approval for its first cancer drug, enasidenib, by the US Food and Drug Administration. [9]
In December 2017, the company filed a New Drug Application with the US FDA for ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. [10]
In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds. [11]
In April 2022, the FDA approved mitapivat as first disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase deficiency. [12]
Corporate governance
As of August 2022 [update], Agios' CEO is Brian Goff. [13]
Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ. [4] [6]
References
- ^ "Agios Reports Fourth Quarter and Full Year 2019 Financial Results – Agios Pharmaceuticals, Inc".
- ^ a b Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. (ed.). The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.
- ^ "About Us".
- ^
a
b
c Pollack, Andrew (February 5, 2012).
"Sloan-Kettering Chief Is Accused of Taking Research".
The New York Times.
- ^ "AGIOS PHARMACEUTICALS, INC". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.
- ^
a
b Huggett, Brady (December 2013).
"Burning Bright".
Nat. Biotechnol. Vol. 31, no. 12. pp. 1068–71.
- ^ "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN. 17 May 2016.
- ^ Williams, Sean (3 June 2016). "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016". The Moteley Fool. Retrieved 13 July 2018.
- ^ "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.
- ^ Agios Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2017.
- ^ "Agios Announces Pricing of $256 Million Public Offering of Common Stock". www.nasdaq.com. Retrieved 2020-03-12.
- ^ "Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency". Agios. Cambridge, MA. 17 February 2022. Retrieved 24 April 2023.
- ^ "Agios Appoints Brian Goff as Chief Executive Officer".
|
| This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
- Pharmaceutical companies of the United States
- Pharmaceutical companies established in 2008
- Companies based in Cambridge, Massachusetts
- Companies listed on the Nasdaq
- Health care companies based in Massachusetts
- 2013 initial public offerings
- 2008 establishments in Massachusetts
- American companies established in 2008
- Medical company stubs